Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTO0308 in Pediatric Patients With Myopia
NCT07790640Phase 3Active, not recruiting
- Sponsor
- Taejoon Pharmaceutical Co., Ltd.
- Start
- Aug 2025
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of SYD-101 in myopia (4 arms), sponsored by Taejoon Pharmaceutical Co., Ltd. Primary endpoint: Change in Spherical Equivalent at 12 months. Started Aug 2025; status: active, not recruiting.
02
Drugs
SYD-101
03
Conditions
myopia
Beyond the preview
Go deeper on NCT07790640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07790640.